Fulcrum Therapeutics (NASDAQ:FULC) Announces Earnings Results

Fulcrum Therapeutics (NASDAQ:FULC) announced its earnings results on Thursday. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.10), FiscalAI reports.

Fulcrum Therapeutics Stock Performance

Shares of Fulcrum Therapeutics stock traded down $0.06 during midday trading on Thursday, hitting $3.68. 2,139,086 shares of the company traded hands, compared to its average volume of 1,591,154. The stock has a market cap of $281.09 million, a price-to-earnings ratio of -3.04 and a beta of 2.82. Fulcrum Therapeutics has a 12 month low of $2.83 and a 12 month high of $15.74. The firm’s fifty day moving average price is $3.74 and its 200-day moving average price is $5.62.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $8.20.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It develops medicines for genetically defined diseases, with research focused on changing gene expression to address the underlying causes of illness. The company’s work has included programs for sickle cell disease and facioscapulohumeral muscular dystrophy, a rare genetic muscle disorder. Its research has explored approaches such as influencing hemoglobin production and modifying disease-related gene activity.